Education
About Us
Working with TipRanks
Follow Us
Electrocore (ECOR)
:ECOR
ECOR Stock Chart & Stats
$5.02
$0.45(2.64%)
At close: 4:00 PM EST
$5.02
$0.45(2.64%)
Day’s Range― - ―
52-Week Range$4.16 - $19.49
Previous CloseN/A
Volume24.66K
Average Volume (3M)46.97K
Market Cap
$40.14M
Enterprise Value$40.75M
Total Cash (Recent Filing)$7.39M
Total Debt (Recent Filing)$4.23M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 13, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding7,995,903
10 Day Avg. Volume53,384
30 Day Avg. Volume46,973
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)16.08
Price to Sales (P/S)4.82
P/FCF Ratio-17.46
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda-3.32
Forecast
1Y Price Target
$16.35Price Target Upside225.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Market OpportunityECOR has only dispensed gammaCore to ~2% of the estimated 600K VA headache patients, which highlights a significant opportunity ahead.
Revenue GrowthECOR's above-consensus 2Q25 revenue growth reflected the commercial traction of Truvaga and VA channel expansion.
Bears Say
Profitability DelaysThe stock is down mainly due to the delayed company-wide profitability.
Valuation ConcernsDespite growth opportunities, ECOR trades at a discount valuation which is justified due to delayed profitability from higher expected operating expenses.
Electrocore News
ECOR FAQ
What was Electrocore’s price range in the past 12 months?
Electrocore lowest stock price was $4.16 and its highest was $19.49 in the past 12 months.
What is Electrocore’s market cap?
Electrocore’s market cap is $40.14M.
When is Electrocore’s upcoming earnings report date?
Electrocore’s upcoming earnings report date is Nov 13, 2025 which is in 27 days.
How were Electrocore’s earnings last quarter?
Electrocore released its earnings results on Aug 06, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.325 by -$0.115.
Is Electrocore overvalued?
According to Wall Street analysts Electrocore’s price is currently Undervalued.
Does Electrocore pay dividends?
Electrocore does not currently pay dividends.
What is Electrocore’s EPS estimate?
Electrocore’s EPS estimate is -0.37.
How many shares outstanding does Electrocore have?
Electrocore has 7,995,903 shares outstanding.
What happened to Electrocore’s price movement after its last earnings report?
Electrocore reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.325. Following the earnings report the stock price went down -29.149%.
Which hedge fund is a major shareholder of Electrocore?
Currently, no hedge funds are holding shares in ECOR
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.35 (225.70% Upside)
$16.35 (225.70% Upside)
Blogger Sentiment
Bullish
ECOR Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $71.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.25%
12-Months-Change
Fundamentals
Return on Equity
-210.58%
Trailing 12-Months
Asset Growth
-34.87%
Trailing 12-Months
Company Description
Electrocore
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
ECOR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and successful acquisitions on the positive side, but also highlighted challenges such as declining prescription revenues and increased operating expenses leading to a higher net loss. The strategy to invest in growth postpones profitability but aims for long-term value creation.View all ECOR earnings summariesECOR Stock 12 Month Forecast
Average Price Target
$16.35
▲(225.70% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Ownership Overview
21.99% Insiders
4.10% Mutual Funds
6.99% Other Institutional Investors
64.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---